Kojin Therapeutics develops targeted therapeutics based on a proprietary approach to cell state and ferroptosis biology. The company has created a ferroptosis-based drug discovery platform that links non-genetic cell-state classifications to known biochemical processes to identify selective therapeutic targets. Its initial pipeline is focused on oncology, including hard-to-treat and drug-resistant cancers, with potential applications in immune-based disorders, fibrosis, and neurodegeneration. Kojin plans to use Series A proceeds to accelerate its discovery platform and advance its pipeline. The company was founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan and is led by acting CEO Amir Nashat, acting President Susan Langer, and CSO Kay Ahn. Kojin launched from Cambridge, Mass., with a $60 million Series A to commercialize its approach.

Total raised

$60M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2021